(NASDAQ: VOR) Vor Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Vor Biopharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VOR's revenue for 2025 to be $1,248,515,470, with the lowest VOR revenue forecast at $1,248,515,470, and the highest VOR revenue forecast at $1,248,515,470. On average, 1 Wall Street analysts forecast VOR's revenue for 2026 to be $1,560,644,338, with the lowest VOR revenue forecast at $1,560,644,338, and the highest VOR revenue forecast at $1,560,644,338.
In 2027, VOR is forecast to generate $7,635,296,357 in revenue, with the lowest revenue forecast at $3,121,288,675 and the highest revenue forecast at $12,149,304,039.